SCHEMBL10043029

SCHEMBL10043029

CCCCCCCCCCCCCCCCOCC(CO[Si](C)(C)C(C)(C)C)OCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 8/20 0.43
PLA2G10 O15496 3/20 0.43
PLA2G1B P04054 2/20 0.42
PLA2G5 P39877 2/20 0.42
TLR2 O60603 8/20 0.39
LPAR1 Q92633 3/20 0.35
LPAR3 Q9UBY5 3/20 0.35
LPAR2 Q9HBW0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25967589 1.00 PLA2G2A (0.43) PLA2G2APLA2G10PLA2G1BPLA2G5TLR2
SCHEMBL25967477 0.93 PLA2G2A (0.43) PLA2G2APLA2G10PLA2G1BPLA2G5TLR2
SCHEMBL30866265 0.86 TLR2 (0.41) PLA2G2APLA2G10PLA2G1BPLA2G5TLR2
SCHEMBL10604671 0.86 PLA2G10 (0.47) PLA2G2APLA2G10PLA2G1BPLA2G5TLR2
SCHEMBL10605748 0.86 PLA2G10 (0.47) PLA2G2APLA2G10PLA2G1BPLA2G5TLR2
SCHEMBL18641859 0.86 PLA2G10 (0.47) PLA2G2APLA2G10PLA2G1BPLA2G5TLR2
SCHEMBL10604578 0.86 PLA2G10 (0.47) PLA2G2APLA2G10PLA2G1BPLA2G5TLR2
SCHEMBL24304580 0.85 PLA2G2A (0.47) PLA2G2APLA2G10PLA2G1BPLA2G5TLR2
SCHEMBL24304605 0.85 PLA2G2A (0.45) PLA2G2APLA2G10PLA2G1BPLA2G5TLR2
SCHEMBL24304365 0.83 PLA2G2A (0.37) PLA2G2APLA2G10PLA2G1BPLA2G5TLR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334235-B2 Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging PHENOMENOME DISCOVERIES INC. (CA) 2016-05-10 US disclosed
US-20130116312-A2 PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING DISEASES OF THE AGING PHENOMENOME DISCOVERIES INC. (CA) 2013-05-09 US disclosed
US-20120035250-A1 PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING DISEASES OF THE AGING PHENOMENOME DISCOVERIES INC. (CA) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035250-A1 PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING DISEASES OF THE AGING PHOSPHO1, SGMS2, MBOAT1 PLA2G2A 25/4885PLA2G10 12/4885PLA2G1B 106/4885
US-20130116312-A2 PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING DISEASES OF THE AGING PHOSPHO1, SGMS2, MBOAT1 PLA2G2A 25/4885PLA2G10 12/4885PLA2G1B 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.